Effects of vitamin D3, calcipotriol and FTY720 on the expression of surface molecules and cytolytic activities of human natural killer cells and dendritic cells

Toxins

Volumn 5, Issue 11, 2013, Pages 1932-1947

  Al Jaderi, Zaidoon ^a   Maghazachi, Azzam A ^a  

^a UNIVERSITY OF OSLO   (Norway)

Author keywords

Calcipotriol; Cytotoxicity; Dendritic cells; FTY720; Natural killer cells; NK17 NK1 cells; Receptors; Vitamin D3

Indexed keywords

CALCIPOTRIOL; CHEMOKINE RECEPTOR CCR6; COLECALCIFEROL; FINGOLIMOD; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NATURAL KILLER CELL RECEPTOR NKG2D;

ARTICLE; CELL STRAIN K 562; CELL SURFACE; CONTROLLED STUDY; CYTOLYSIS; DENDRITIC CELL; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; NATURAL KILLER CELL; PROTEIN EXPRESSION; UPREGULATION;

CALCITRIOL; CELL LINE, TUMOR; CHOLECALCIFEROL; CYTOTOXICITY, IMMUNOLOGIC; DENDRITIC CELLS; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-2; K562 CELLS; KILLER CELLS, NATURAL; MEMBRANE PROTEINS; MULTIPLE SCLEROSIS; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 2; NATURAL CYTOTOXICITY TRIGGERING RECEPTOR 3; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; PROPYLENE GLYCOLS; RECEPTORS, CCR6; RECEPTORS, CCR7; SPHINGOSINE; UP-REGULATION;

EID: 84886994204     PISSN: 20726651     EISSN: None     Source Type: Journal    
DOI: 10.3390/toxins5111932     Document Type: Article

References (48)

1. Fauriat, C.; Long, E.O.; Ljunggren, H.G.; Bryceson, Y.T. Regulation of human NK-cell cytokine and chemokie production by target cell recognition. Blood 2010, 115, 2167-2176.
2. Maghazachi, A.A. Compartmentalization of human natural killer cells. Mol. Immunol. 2005, 42, 523-529.
3. Wood, S.M.; Ljunggren, H.G.; Bryceson, Y.T. Insights into NK cell biology from human genetics and disease associations. Cell. Mol. Life Sci. 2011, 68, 3479-3493.
4. Maghazchi, A.A. On the role of natural killer cells in neurodegenerative diseases. Toxins 2013, 5, 363-375.
5. Maghazachi, A.A. Role of natural killer cells in multiple sclerosis. ISRN Immunol. 2012, doi:10.5402/2012/795075.
6. Benczur, M.; Petranyl, G.G.; Palffy, G.; Varga, M.; Talas, M.; Kotsy, B.; Földes, I.; Hollán, S.R. Dysfunction of natural killer cells in multiple sclerosis: A possible pathogenetic factor. Clin. Exp. Immunol. 1980, 39, 657-662.
7. Kastrukoff, L.F.; Morgan, N.G.; Aziz, T.M.; Zecchini, D.; Berkowitz, J.; Paty, D.W. Natural killer (NK) cells in chronic progressive multiple sclerosis patients treated with lymphoblastoid interferon. J. Neuroimmunol. 1998, 20, 15-23.
8. Grunebaum, E.; Malatzky-Goshen, E.; Shoenfeld, Y. Natural killer cells and autoimmunity. Immunol. Res. 1989, 8, 292-304.
9. Zhang, B.; Yamamura, T.; Kondo, T.; Fujiwara, M.; Tabira, T. Regulation of experimental autoimmune encephalomyelitis by natural killer (NK) cells. J. Exp. Med. 1997, 186, 1677-1687.
10. Kaur, G.; Trowsdale, J.; Fugger, L. Natural killer cells and their receptors in multiple sclerosis. Brain 2013, 136, 2657-2676.
11. Winkler-Pickett, R.; Young, H.A.; Cherry, J.M.; Diehl, J.; Wine, J.; Back, T.; Bere, W.E.; Mason, A.T.; Ortaldo, J.R. In vivo regulation of experimental autoimmune encephalomyelitis by NK cells: Alteration of primary adaptive responses. J. Immunol. 2008, 180, 4495-4506.
12. Vollmer, T.L.; Liu, R.; Price, M.; Rhodes, S.; La, C.A.; Shi, F.D. Differential effects of IL-21 during initiation and progression of autoimmunity against neuroantigen. J. Immunol. 2005, 174, 2696-2701.
13. Sand, K.L.; Rolin, J.; Knudsen, E.; Al-Falahi, Y.; Maghazachi, A.A. Modulation of natural killer cell cytotoxicity and cytokine release by the drug glatiramer acetate. Cell. Mol. Life Sci. 2009, 66, 1446-1456.
14. Al-Falahi, Y.; Sand, K.L.; Knudsen, E.; Damaj, B.B.; Rolin, J.; Maghazachi, A.A. Splenic natural killer cell activity in two models of experimental neurodegenerative diseases. J. Cell. Mol. Med. 2009, 13, 2693-2703.
15. Høglund, R.; Harbo, H.F.; Holmøy, T.; Maghazachi, A.A. A one year follow-up study of natural killer and dendritic cells activities in multiple sclerosis patients receiving glatiramer acetate. PLoS One 2013, 8, e62237.
16. Hestvick, A.L.K. The Double-edged sword of autoimmunity: Lessons from multiple sclerosis. Toxins 2010, 2, 856-877.
17. Ascherio, A.; Munger, K.L. Environmental risk factors for multiple sclerosis. Part II: Noninfectious factors. Ann. Neurol. 2007, 61, 504-513.
18. Ascherio, A.; Munger, K.L.; Simon, K.C. Vitamin D and multiple sclerosis. Lancet Neurol. 2010, 9, 599-612.
19. Brustad, M.; Sandanger, T.; Aksnes, L.; Lund, E. Vitamin D status in a rural population of northern Norway with high fish liver consumption. Public Health Nutr. 2004, 7, 783-789.
20. Lemire, J.M.; Archer, D.C. 1,25-dihydroxyvitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J. Clin. Investig. 1991, 87, 1103-1107.
21. Cantorna, M.T.; Hayes, C.E.; DeLuca, H.F. 1,25-Dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc. Natl. Acad. Sci. USA 1996, 93, 7861-7864.
22. Burton, J.M.; Kimball, S.; Vieth, R.; Bar-Or, A.; Dosch, H.M.; Cheung, R.; Gagne, D.; D'Souza, C.; Ursell, M.; O'Connor, P. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010, 74, 1852-1859.
23. Smolders, J.; Thewissen, M.; Peelen, E.; Menheere, P.; Tervaert, J.W.; Damoiseaux, J.; Hupperts, R. Vitamin D status is positively correlated with regulatory T cell function in patients with multiple sclerosis. PLoS One 2009, 4, e6635.
24. Smolders, J.; Peelen, E.; Thewissen, M.; Tervaert, J.W.; Menheere, P.; Hupperts, R.; Damoiseaux, J. Safety and T cell modulating effects of high hose vitamin D3 supplementation in multiple sclerosis. PLoS One 2010, 5, e15235.
25. Wergeland, S.; Torkildsen, Ø.; Myhr, K.M.; Aksnes, L.; Mørk, S.J.; Bø, L. Dietary vitamin D3 supplements reduce demyelination in the cuprizone model. PLoS One 2011, 6, e26262.
26. Brinkmann, V. Sphingosine 1-phosphate receptors in health and disease: Mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol. Ther. 2007, 115, 84-105.
27. Kveberg, L.; Bryceson, Y.; Inngjerdingen, M.; Rolstad, B.; Maghazachi, A.A. Sphingosine 1 phosphate induces the chemotaxis of human natural killer cells. Role for heterotrimeric G proteins and phosphoinositide 3 kinases. Eur. J. Immunol. 2002, 32, 1856-1864.
28. Lagadari, M.; Lehmann, K.; Ziemer, M.; Truta-Feles, K.; Berod, L.; Idzko, M.; Barz, D.; Kamradt, T.; Maghazachi, A.A.; Norgauer, J. Sphingosine-1-phosphate inhibits the cytotoxic activity of NK cells via Gs protein-mediated signaling. Int. J. Oncol. 2009, 34, 287-288.
29. Rolin, J.; Sand, K.L.; Knudsen, E.; Maghazachi, A.A. FTY720 and SEW2871 reverse the inhibitory effect of S1P on natural killer cell mediated lysis of K562 tumor cells and dendritic cells but not on cytokine release. Cancer Immunol. Immnuother. 2010, 59, 575-586.
30. Pandya, A.D.; Al-Jaderi, Z.; Høglund, R.A.; Holmøy, T.; Harbo, H.F.; Norgauer, J.; Maghazachi, A.A. Identification of human NK17/NK1 cells. PLoS One 2011, 6, e26780.
31. Godiska, R.; Chantry, D.; Raport, C.J.; Sozzani, S.; Allavena, P.; Leviten, D.; Mantovani, A.; Gray, P.W. Human macrophage-derived chemokine (MDC), a novel chemoattractant for monocytes, monocyte-derived dendritic cells, and natural killer cells. J. Exp. Med. 1997, 185, 1595-1604.
32. Székely, J.I.; Pataki, Á. Effects of vitamin D on immune disorders with special regard to asthma, COPD and autoimmune diseases: A short review. Experts Rev. 2012, 6, 683-704.
33. Penna, G.; Amuchastegui, S.; Laverny, G.; Adorini, L. Vitamin D receptor agonists in the treatment of autoimmune diseases: Selective targeting of myeloid but not plasmacytoid dendritic cells. J. Bone Miner. Res. 2007, 22, V69-V73.
34. Motrich, R.D.; van Etten, E.; Depovere, J.; Riera, C.M.; Rivero, V.E.; Mathieu, C. Impact of vitamin D receptor activity on experimental autoimmune prostatitis. J. Autoimmun. 2009, 32, 140-148.
35. Gauzzi, M.C.; Purificato, C.; Donato, K.; Jin, Y.; Wang, L.; Daniel, K.C.; Maghazachi, A.A.; Belardelli, F.; Adorini, L.; Gessani, S. Suppressive effect of 1alpha,25-dihydroxyvitamin D3 on type I IFN-mediated monocyte differentiation into dendritic cells: Impairment of functional activities and chemotaxis. J. Immunol. 2005, 174, 270-276.
36. Lee, J.H.; Park, S.; Cheon, S.; Lee, J.H.; Kim, S.; Hur, D.Y.; Kim, T.S.; Yoon, S.R.; Yang, Y.; Bang, S.I.; et al. 1,25-Dihydroxyvitamin D3 enhances NK susceptibility of human melanoma cells via Hsp60-mediated FAS expression. Eur. J. Immunol. 2011, 41, 2937-2946.
37. El-Shazly, A.E.; Lefebvre, P.P. Modulation of NK cell autocrine-induced eosinophil chemotaxis by interleukin-15 and vitamin D3: A possible NK-eosinophil crosstalk via IL-8 in the pathophysiology of allergic rhinitis. Mediat. Inflamm. 2011, doi:10.1155/2011/373589.
38. Brandt, C.S.; Baratin, M.; Yi, E.C.; Kennedy, J.; Gao, Z.; Fox, B.; Haldeman, B.; Ostrander, C.D.; Kaifu, T.; Chabannon, C.; et al. The B7 family member B7-H6 is a tumor cell ligand for the activating natural killer cell receptor NKp30 in humans. J. Exp. Med. 2009, 206, 1495-1503.
39. Simhadri, V.R.; Reiners, K.S.; Hansen, H.P.; Topolar, D.; Simhadri, V.L.; Nohroudi, K.; Kufer, T.A.; Engert, A.; Pogge von Strandmann, E. Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One 2008, 3, e3377.
40. Marras, F.; Nicco, E.; Bozzano, F.; Di Biagio, A.; Dentone, C.; Pontali, E.; Boni, S.; Setti, M.; Orofino, G.; Mantia, E.; et al. Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proc. Natl. Acad. Sci. USA 2013, 110, 11970-11975.
41. De Maria, A.; Biassoni, R.; Fogli, M.; Rizzi, M.; Cantoni, C.; Costa, P.; Conte, R.; Mavilio, D.; Ensoli, B.; Cafaro, A.; et al. Identification, molecular cloning and functional characterization of NKp46 and NKp30 natural cytotoxicity receptors in Macaca fascicularis NK cells. Eur. J. Immunol. 2001, 31, 3546-3556.
42. Arnon, T.I.; Achdout, H.; Lieberman, N.; Gazit, R.; Gonen-Gross, T.; Katz, G.; Bar-Ilan, A.; Bloushtain, N.; Lev, M.; Joseph, A.; et al. The mechanisms controlling the recognition of tumor-and virus-infected cells by NKp46. Blood 2004, 103, 664-672.
43. Maghazachi, A.A. Insights into seven and single transmembrane-spanning domain receptors and their signaling pathways in human natural killer cells. Pharmacol. Rev. 2005, 57, 339-357.
44. Rach-Regué, D.; Grau-López, L.; Naranjo-Gómez, M.; Ramo-Tello, C.; Pujol-Borrell, R.; Martínez-Cáceres, E.; Borràs, F.E. Stable antigen-specific T-cell hyporesponsiveness induced by tolerogenic dendritic cells from multiple sclerosis patients. Eur. J. Immunol. 2012, 42, 771-782.
45. Kappos, L.; Antel, J.; Comi, G.; Montalban, X.; O'Connor, P.; Polman, C.H.; Haas, T.; Korn, A.A.; Karlsson, G.; Radue, E.W. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N. Engl. J. Med. 2006, 355, 1124-1140.
46. O'Connor, P.; Comi, G.; Montalban, X.; Antel, J.; Radue, E.W.; de Vera, A.; Pohlmann, H.; Kappos, L. FTY720 D2201 Study Group: Oral fingolimod (FTY720) in multiple sclerosis: Two-year results of a phase II extension study. Neurology 2009, 72, 73-79.
47. Pyne, S.; Pyne, N.J. New perspectives on the role of sphingosine 1-phosphate in cancer. Handb. Exp. Pharmacol. 2013, 216, 55-71.
48. Jin, Y.; Knudsen, E.; Wang, L.; Bryceson, Y.; Damaj, B.; Gessani, S.; Maghazachi, A.A. Sphingosine 1-phosphate is a novel inhibitor of T-cell proliferation. Blood 2003, 101, 4909-4915.